A new publication referencing glatiramer was posted on September 18, 2026. The paper, titled "Engineering human myelin microphysiological systems for testing patient treatment response in multiple sclerosis," appeared on bioRxiv, the preprint server for biology.
This is a preprint publication, meaning it has not yet completed formal peer review. The listing identifies the work under PubMed ID 42779865 and is dated to its posting on the bioRxiv platform.
No findings, results, or conclusions from the publication are included in this brief. The title indicates the work involves engineering microphysiological systems using human myelin, intended for testing treatment responses in multiple sclerosis, a condition for which glatiramer is an approved therapy.
Readers should consult the original preprint via the source link for full methodology and any reported outcomes. As a preprint, the content may be revised before or upon formal publication in a peer reviewed journal.
For more background on glatiramer, including its approved status and general information, see the compound overview.